 By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT On July 14, 2020, Verrica Pharmaceutical VRCA announced that it had received a Complete Response Letter CRL from the FDA for its VP-102 YCANTH new drug application NDA, which was submitted last September. Verrica had completed Phase III CAMP-1 and CAMP-2 pivotal trials which demonstrated safety and efficacy of the 